Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer

•pMMR/MSS CRCs are inherently resistant to ICIs.•Preclinical data suggest a synergism between multi-kinase inhibitors and ICIs.•Regorafenib plus ICIs has been investigated in pMMR/MSS CRC with variable results.•pMMR/MSS CRC patients without liver metastases benefit most from such combination.•Ongoing studies will shed further light into the potential of regorafenib plus ICIs in pMMR/MSS CRC.